Researchers from Oxford University's Department of Paediatrics have successfully completed the first human trial of a vaccine for a common virus that is particularly dangerous to infants.
Oxford University doctors and scientists are performing the second phase of clinical studies of an experimental Ebola vaccine regimen. The study is part of the EBOVAC2 project, a collaborative programme involving the University of Oxford, French Institute of Health and Medical Research (INSERM) as project coordinator, London School of Hygiene & Tropical Medicine, Le Centre Muraz, Inserm Transfert (IT) and the Janssen Pharmaceutical Companies of Johnson & Johnson.
The brains of babies \u2018light up\u2019 in a very similar way to adults when exposed to the same painful stimulus, a pioneering Oxford University brain scanning study has discovered. It suggests that babies experience pain much like adults.
The Oxford Vaccine Group in the Department is currently looking to recruit healthy adults aged between 18 to 60 in a study investigating how the adult immune system responds to a new meningococcal B vaccine.
Oxford University doctors and scientists are starting the first safety trial of an experimental preventative Ebola vaccine regimen being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen).The Oxford Vaccine Group, part of the University of Oxford Department of Paediatrics, aims to have vaccinated all 72 healthy adult volunteers by the end of January.\r\n \r\n
Today\u2019s Research Excellence Framework (REF 2014) results confirm the University of Oxford\u2019s world leading position in medical sciences research.
The rapid evolution of HIV, which has allowed the virus to develop resistance to patients' natural immunity, is at the same time slowing the virus' ability to cause AIDS, according to new research Funded by the Wellcome Trust.
Medical professionals used to believe that babies simply don\u2019t feel pain. Building on critical work started in Oxford in the 1980s that proved them wrong, Dr Rebeccah Slater is developing new ways to see inside the minds of newborns.
The HIV Research Group, led by Professor Philip Goulder of the Department of Paediatrics, have been awarded a multi-million pound, five year Wellcome Trust Senior Investigator award to further their work into HIV disease limitation.
The Oxford Vaccine Group, part of the University of Oxford Department of Paediatrics, have been successful in gaining funding from the European Vaccine Initiative and the Bill and Melinda Gates Foundation for new research into Salmonella Paratyphii.
Oxford Vaccine Group director and Professor of Paediatric Infection at the Department of Paediatrics, Professor Andrew Pollard, discusses the work of the Oxford Vaccine Group
On March 21st 2014 the MenB vaccine was recommended for introduction into the UK schedule. In this short film, experts and a mother whose child was disabled by MenB infection talk about the new vaccine.
Professor Irene Roberts, Professor of Paediatric Haematology at the University of Oxford Department of Paediatrics, has been appointed as Theme Lead for Non-Malignant Haematological Disorders for the National Institute of Health Research Rare Diseases Translational Research Collaboration.
![\"\"](\"https://www.paediatrics.ox.ac.uk/news/prestigious-nihr-grant-awarded-to-rebeccah-slater/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n